Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0900 • ACR Convergence 2025
Profiling of Novel Autoantibodies for Prediction of Disease Activity in ANCA-Associated Vasculitis
Charlotta Preger¹, Maria Aspenberg¹, Metta Berenpas¹, Armita Dwivedi², Juliana Bordignon Draibe³, Peter Nilsson¹, Mark A. Little² and Elisa Pin¹, ¹Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden, ²Trinity Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland, ³Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
Background/Purpose: ANCA-associated vasculitides (AAV) are a heterogenous group systemic autoimmune diseases characterized by necrotizing inflammation of small blood vessels requiring prompt initiation of immunosuppressive treatment…
Abstract Number: 0853 • ACR Convergence 2025
Olink Proteomics Identifies Macrophage Pro-inflammatory Proteins in Maternal Sera Predictive of Fetal Atrioventricular Block Independent of Maternal Health Status
Philip Carlucci¹, Mala Masson², Colin Phoon³, Ashley Roman³, Peter Izmirly⁴, Amit Saxena⁵, Michael Belmont⁶, Christina Penfield³, Young Mi Lee³, Julie Nusbaum⁶, Andrew Rubenstein³, Nalani Sachan³, Joel Guthridge⁷, Judith James⁷, Elena Sinkovskaya⁸, Alfred Abuhamad⁸, Gary Satou⁹, Whitnee Hogan¹⁰, Anita Moon-Grady¹¹, Lisa Howley¹², Mary Donofrio¹³, Stephanie Levasseur¹⁴, Miwa Geiger¹⁵, Sonal Owens¹⁶, Kristopher Cumbermack¹⁷, Jyothi Matta¹⁸, Gary Joffe¹⁹, Christopher Lindblade²⁰, Caitlin Haxel²¹, Katherine Kohari²², Joshua Copel²², James Strainic²³, Tam Doan²⁴, Conisha Holloman²⁴, Stacy Killen²⁵, Theresa Tacy²⁶, Michelle Kaplinski²⁶, Nicola Fraser³, Kelly Ruggles²⁷, Bettina Cuneo²⁸, Jill Buyon³ and Robert Clancy¹⁴, ¹New York University School of Medicine, New York, NY, ²NYU Langone Medical Center- Division of Rheumatology, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁶NYU Langone Health, New York, NY, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Eastern Virginia Medical School, Norfolk, VA, ⁹University of California Los Angeles, Los Angeles, CA, ¹⁰University of Utah, Salt Lake City, UT, ¹¹University of California San Francisco, San Francisco, CA, ¹²Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹³Children's National Hospital, Washington, DC, ¹⁴Columbia University, New York, NY, ¹⁵Mount Sinai School of Medicine, New York, NY, ¹⁶University of Michigan, Ann Arbo, MI, ¹⁷University of Kentucky, Lexington, KY, ¹⁸University of Louisville, Louisville, KY, ¹⁹Perinatal Associates of New Mexico, Albuquerque, NM, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹University of Vermont Children's Hospital, Burlington, VT, ²²Yale University, New Haven, CT, ²³UH Rainbow Babies, Cleveland, OH, ²⁴Baylor College of Medicine, Houston, TX, ²⁵Vanderbilt University, Nashville, TN, ²⁶Stanford University, Stanford, CA, ²⁷NYU Grossman School of Medicine, Brooklyn, NY, ²⁸University of Arizona College of Medicine, Tucson, AZ
Background/Purpose: Fetal atrioventricular block (fAVB) is presumed dependent on the transplacental passage of SSA/Ro52/60kD autoantibodies that bind to apoptotic fetal cardiomyocytes, triggering macrophage activation and…
Abstract Number: 0248 • ACR Convergence 2025
Clinical and serological characteristics of anti-Ku autoantibodies in a Hispanic cohort
Emmanuel Dominguez-Chapa¹, Angel Kevin Garza-Elizondo², Karina Deciderio-Pavon³, Rosa Arvizu-Rivera⁴, Jesus Alberto Cardenas-de la Garza⁵, Miguel Villarreal-Alarcón⁶ and Dionicio A. Galarza-Delgado⁷, ¹Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo Leon, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Nuevo León, Mexico, ⁷Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Anti-Ku antibodies are rare myositis-associated antibodies directed against a DNA-binding heterodimer involved in DNA repair. Anti-Ku positivity may be associated with a distinct clinical…
Abstract Number: 2499 • ACR Convergence 2025
Concomitant Anti-Ro/SSA Antibodies in Systemic Sclerosis Patients is Associated with Risks Beyond Dryness
Rachael Gordon¹, Leah Wunsch², Maureen Lauffoon¹, Thomas Medsger, Jr³ and Robyn Domsic¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, Verona, PA
Background/Purpose: Sjogren’s disease (SjD) is a common systemic autoimmune disorder characterized by progressive inflammation of the exocrine glands, resulting in dry eyes and dry mouth.…
Abstract Number: 2335 • ACR Convergence 2025
The 14-3-3 eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain.
Walter P. Maksymowych¹, Raj Sengupta², Anthony Marotta³, Stephanie Wichuk⁴, Charlotte Cavill⁵, Stephen Bleakley³ and Norma Biln⁶, ¹Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ²Royal National Hospital for Rheumatic Diseases, Bath, England, United Kingdom, ³Augurex Life Sciences Corp, Vancouver, BC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Royal United Hospitals Bath NHS Foundation Trust, Bath, England, United Kingdom, ⁶Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: Reducing diagnostic delay for people presenting with back pain who have axial spondyloarthritis (axSpA) has become a clinical imperative since effective treatments can limit…
Abstract Number: 1838 • ACR Convergence 2025
Differential Expression Of Activation Markers On dsDNA-reactive B-cells Between Healthy Subjects And SLE Patients Reveals Unconventional Extrafollicular Activation In SLE
Lars Van Vliet, Annemarie Dorjée, René Toes and Jolien Suurmond, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-dsDNA IgG antibodies are a hallmark of systemic lupus erythematosus (SLE), an autoimmune disease characterized by chronic inflammation and multi-organ damage. Evidence suggests that…
Abstract Number: 1379 • ACR Convergence 2025
Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort
Biji T Kurien¹, Martha Tsaliki² and R Hal Scofield¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²OMRF, Oklahoma City, OK
Background/Purpose: Renal involvement in primary Sjögren’s disease (pSjD) is a well-known extraglandular manifestation with a prevalence of 5-14% in several studies. Mostly, it affects the…
Abstract Number: 0897 • ACR Convergence 2025
APECED Disease Reorganizes The B Cell Compartment Toward Alternatively Activated Subsets
william Galbavy, Hyunjin Kim, Brian Klotz, Marine Malbec, Carley Tasker, Eva Conde, Andrea Vecchione, Seblewongel Asrat, Benjamin Daniel, Weikeat Lim, Andre Limnander and Jamie Orengo, Regeneron, Tarrytown, NY
Background/Purpose: Autoimmune PolyEndocrinopathy Candidiasis Ectodermal Dystrophy (APECED) is a rare syndrome of multi-organ autoimmunity driven by the presence of self-reactive T cells and autoantibodies caused…
Abstract Number: 0773 • ACR Convergence 2025
Clinical Significance of Anti-MDA5 Epitope Antibodies as Prognostic Indicators for Interstitial Lung Disease With or Without Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima², Motohiro Nonaka³, Norimichi Nomura⁴, Atsubumi Ogawa¹, Yasuhiro Nohda¹, Mirei Shirakashi², Ryosuke Hiwa¹, Hideaki Tsuji¹, Hajime Yoshifuji², Shogo Matsuda⁵, Masao Katsushima⁶, Michinori Ishitoku⁷, Yusuke Yoshida⁷, Yasuyuki Todoroki⁸, Satoshi Kubo⁹, Tomohiro Handa¹⁰, Hiromi Tomioka¹¹, Ryo Tachikawa¹², Keisuke Tomii¹², Kiminobu Tanizawa¹³, Toru Arai¹⁴, Takuya Kotani¹⁵, Motomu Hashimoto¹⁶, Shintaro Hirata⁷, Yoshiya Tanaka¹⁷, Tsuneyo Mimori¹⁸ and Akio Morinobu¹⁹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ³Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁶Department of Clinical Immunology, Osaka Metropolitan Graduate School of Medicine, Osaka, Japan, ⁷Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ⁸Department of Molecular Targeted Therapies, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Department of Molecular Targeted Therapies (DMTT), University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁰Department of Advanced Medicine for Respiratory Failure and Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹¹Department of Respiratory Medicine, Kobe City Medical Center West Hospital, Kobe, Japan, ¹²Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan, ¹³Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan, ¹⁴Clinical Research Center, NHO Kinki-Chuo Chest Medical Center, Sakai, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Osaka, Japan, ¹⁶Osaka Metropolitan University, Osaka, Japan, ¹⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁸Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ¹⁹Kyoto University, Kyoto, Kyoto, Japan
Background/Purpose: Melanoma differentiation-associated gene 5 (MDA5) is a cytoplasmic RNA sensor and activates the innate immune response. Autoantibodies against MDA5 are associated with rapidly progressive…
Abstract Number: 0236 • ACR Convergence 2025
Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease
Laura Bucci¹, Sebastian Böltz¹, Melanie Hagen¹, Danae-Mona Nöthling¹, Tobias Rothe², Carlo Tur¹, Andreas Wirsching¹, Janina Auth³, jochen wacker¹, Markus Eckstein⁴, Stefano Alivernini⁵, Aline Bozec¹, Christina Bergmann¹, Maria Antonietta D'Agostino⁶, Maria Gabriella Raimondo¹, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: T cell engagers (TCEs) are a promising therapeutic strategy to treat autoimmune diseases (AID). However, long-term data remain limited.Methods: Patients with treatment-refractory AID were…
Abstract Number: 2496 • ACR Convergence 2025
Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score
Philip Yee¹, medha kanitkar², stefano rodolfi³, Voon H. Ong² and Christopher Denton⁴, ¹Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ³University College London, London, United Kingdom, ⁴University College London, UK, London, United Kingdom
Background/Purpose: Evaluating disease modification in systemic sclerosis (SSc) is challenging and requires long term studies. This is especially relevant to limited cutaneous (lc)SSc where severe…
Abstract Number: 2255 • ACR Convergence 2025
Diagnostic Accuracy of Anti-Carbamylated Protein Antibodies in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Pannathorn Nakaphan¹, Patavee Pajareya², Priabprat Jansem³, Somkiat Phutinart², Nattanicha Chaisrimaneepan⁴ and Noppachai Siranart², ¹Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, ²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX
Background/Purpose: Anti-carbamylated protein antibodies (anti-CarP Ab) are emerging serologic markers in rheumatoid arthritis (RA). Anti-CarP Ab has a controversial diagnostic utility in RA but may…
Abstract Number: 1814 • ACR Convergence 2025
Trapped in the NET: Impaired DNase function and targeted antibodies in the pathogenesis of pediatric lupus nephritis
Sohei Makita¹, Joyce Hui-Yuen², Bharati Matta³, Betsy Barnes⁴, Jenna Battaglia⁵, Tatiana Borja⁶, Boris Reizis⁷, Lydia Thomas⁸ and Kim Simpfendorfer⁹, ¹NYU, New York, ²North Shore LIJ Health System, Great Neck, NY, ³The Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Northwell Health, Manhasset, NY, ⁵Northwell Health, Manhasset, ⁶Northwell Health- Cohen Children’s Medical Center, Elmhurst, NY, ⁷New York University Grossman School of Medicine, New York, NY, ⁸Northwell Health - Cohen Children's Medical Center, Lake Success, NY, ⁹Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Up to 80% of patients with pediatric systemic lupus erythematosus (pSLE) can present with renal abnormalities. Treatment of pSLE is often difficult and includes…
Abstract Number: 1330 • ACR Convergence 2025
Sex and reproductive stage modify the role of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis and differences reflect effects on inflammation and cholesterol metabolism
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Matthew Budoff¹ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: Endogenous estrogens associate with cardioprotective benefits in the general population. Yet, dual pro- and anti-inflammatory effects were described in autoimmune states depending on concentration,…
Abstract Number: 0711 • ACR Convergence 2025
Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Autoantibodies to GBM, PR3, and MPO: A Multicenter Evaluation
Natalia Swierczynska¹, Ruaridh Armour¹, Anthony Yau¹, Enn Rusi¹, Mark Hooper¹, Jason Sillitoe², Caroline Wilson², Paula Griffiths³, Tariq El-Shanawany³, Faye Sims⁴, Gerber Gomez⁵, Christian Fischer⁵, Michael Hausmann⁶ and Helen Laird¹, ¹Research & Development, AliveDx, Edinburgh, Scotland, United Kingdom, ²North East Innovation Lab, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ³Immunology Department, Laboratory Medicine, Swansea Bay University Health Board, UK. Cardiff and Vale UHB, Swansea, Wales, United Kingdom, ⁴Clinical Biochemistry and Immunology Department Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, England, United Kingdom, ⁵Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland, ⁶AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA), including those directed to myeloperoxidase (MPO) and proteinase 3 (PR3) as well as antibodies against anti-glomerular basement membrane (anti-GBM) are…

« Previous Page
1
…
5
6
7
8
9
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].